News Snapshot:
BEIJING (Reuters) - A shortage of lab monkeys and a focus on developing a COVID-19 treatment have prompted Shanghai Junshi Biosciences to push back clinical trials of some other drugs, an executive at U.S. drugmaker Eli Lilly's Chinese partner said. Junshi's experimental COVID-19 antibody treatment, JS016, is in early to mid-stage trials in the United States and Eli Lilly plans to combine it with another candidate and apply for a U.S. emergency use authorization later this month. Feng Hui, chief operating officer at Junshi said in a call with investors on Friday that the monkeys used to evaluate the safety...